Top 7 Trends in Pharma Marketing for 2015

Source: PMLive

Here are the top 7 pharma marketing trends we expect big things from this year:

1. Patient Empowerment
2. Wearable Technology
3. Virtual Reality
4. Storytelling
5. Using biomarkers
6. Marketing and Medical Automation
7. Data, Security, and Privacy

They are by no means exhaustive and we will continue to share our views on what is having an impact and transforming the wider healthcare sector throughout the year.  Let us know whether you agree and your predictions for the year ahead. 

The 14 drugs most likely to top global pharma sales in 2015 and 2020

BioPharma Dive | By Sy Mukherjee

Earlier this week, BioPharma Dive reported on the 11 biggest expected drug launches to watch out for in 2015. BMS's anti-PD-1 drug Opdivo and PCSK9 cholesterol inhibitors from Sanofi and Amgen are expected to comprise some of the biggest launches in the industry and to eventually reach blockbuster status.
But there's plenty of already-approved drugs on the market right now that will likely make 2015 yet another massive year for pharma sales worldwide, according to equity analysts' projections aggregated in a big new report (gated) from EvaluatePharma. Old reliables like AbbVie's Humira and red-hot new hep C pills Sovaldi and Harvoni from Gilead Sciences are all expected to reach the upper tiers of marketing successes next year. But by 2020, several of the top 2010 products will probably fall off the list and be replaced with more recent potential blockbusters, so 14 drugs total are expected to rule the global pharma sales landscape over the next six years.
Here are the 10 meds projected to top global sales in 2015 (note: all images in this post are expandable; just click on a given chart if you have trouble reading the data):

The only recently-approved drugs that make the top 10 cut next year are Sovaldi and Harvoni. One important thing to keep in mind: Sovaldi/Harvoni sales are lumped together in this analysis, so technically, either of those two Gilead products alone would fall short of expected sales for AbbVie's anti-inflammatory Humira, the current top-selling drug in the world. But one interesting aspect of the EvalutePharma report is that it tracks how the top 2015 contenders will perform in 2020 (and vic versa).